A Prospective Study on the Efficacy of Levonorgestrel-Releasing Intrauterine Device in Abnormal Uterine Bleeding
Creators
- 1. Assistant Professor Department of Obstetrics and Gynaecology, Andhra Medical College King George Hospital, Visakhapatnam, Andhra Pradesh, India
- 2. Postgraduate, Department of Obstetrics and Gynaecology, Andhra Medical College King George Hospital, Visakhapatnam, Andhra Pradesh, India
Description
Background: In This Study, We Wanted To Evaluate The Efficacy Of Levonorgestrel-Releasing Intrauterine Devices In The Treatment Of Abnormal Uterine Bleeding With Respect To A Decrease In Menstrual Blood Loss, Improvement In Quality Of Life, Acceptability, And Complications. Materials and Methods: This Was A Hospital-Based Prospective Observational Study Conducted Among Patients Aged 30 – 50 Years With Abnormal Uterine Bleeding (Aub), Presenting To The Department Of Obstetrics And Gynaecology, King George Hospital (Kgh), Visakhapatnam For 2 Years From November 2019 To October 2021. Results: Levonorgestrel Intrauterine System Is A Safe, Effective, And Highly Acceptable Mode Of Treatment For Abnormal Uterine Bleeding Which Helps Women For A Smooth Transition To Menopause. It Is Associated With Minimal Side Effects And A High Satisfaction Rate. Also, It Is A Very Good Alternative To Medical And Surgical Treatment For Heavy Menstrual Bleeding In Benign Conditions With High Efficacy And Cost-Effectiveness. It Is The Best Innovative Method For The Treatment Of Abnormal Uterine Bleeding. Hence Consider Lng-Ius As A One-Stop Answer To Aub Before Deciding On A Hysterectomy. Conclusion: About One-Third Of The Outpatients Visiting Gynaecological Opd, Present With The Complaint Of Abnormal Uterine Bleeding. The Normal Menstrual Cycle Interval Is 24-38 Days. Normal Menstrual Flow Lasts For 4.5-8 Days And Normal Menstrual Blood Loss Is Around 5-80 Ml. Levonorgestrel Intrauterine System Is A Safe, Effective, And Highly Acceptable Mode Of Treatment For Abnormal Uterine Bleeding Which Helps Women For A Smooth Transition To Menopause. It Is Associated With Minimal Side Effects And A High Satisfaction Rate. It Is A Very Good Alternative To Medical And Surgical Treatment For Heavy Menstrual Bleeding In Benign Conditions With High Efficacy And Cost-Effectiveness. With This Lng-Ius We Can Even Avoid The Systemic Side Effects Caused By Cocs Like Thromboembolism, Weight Gain, Mood Changes, And Breakthrough Bleeding Which Also Requires Less Skill And No Operative Morbidity. Despite All The Limitations, It Is The Best Innovative Method For The Treatment Of Abnormal Uterine Bleeding. Hence Consider Lng-Ius As A One-Stop Answer To Aub Before Deciding On A Hysterectomy.
Abstract (English)
Background: In This Study, We Wanted To Evaluate The Efficacy Of Levonorgestrel-Releasing Intrauterine Devices In The Treatment Of Abnormal Uterine Bleeding With Respect To A Decrease In Menstrual Blood Loss, Improvement In Quality Of Life, Acceptability, And Complications. Materials and Methods: This Was A Hospital-Based Prospective Observational Study Conducted Among Patients Aged 30 – 50 Years With Abnormal Uterine Bleeding (Aub), Presenting To The Department Of Obstetrics And Gynaecology, King George Hospital (Kgh), Visakhapatnam For 2 Years From November 2019 To October 2021. Results: Levonorgestrel Intrauterine System Is A Safe, Effective, And Highly Acceptable Mode Of Treatment For Abnormal Uterine Bleeding Which Helps Women For A Smooth Transition To Menopause. It Is Associated With Minimal Side Effects And A High Satisfaction Rate. Also, It Is A Very Good Alternative To Medical And Surgical Treatment For Heavy Menstrual Bleeding In Benign Conditions With High Efficacy And Cost-Effectiveness. It Is The Best Innovative Method For The Treatment Of Abnormal Uterine Bleeding. Hence Consider Lng-Ius As A One-Stop Answer To Aub Before Deciding On A Hysterectomy. Conclusion: About One-Third Of The Outpatients Visiting Gynaecological Opd, Present With The Complaint Of Abnormal Uterine Bleeding. The Normal Menstrual Cycle Interval Is 24-38 Days. Normal Menstrual Flow Lasts For 4.5-8 Days And Normal Menstrual Blood Loss Is Around 5-80 Ml. Levonorgestrel Intrauterine System Is A Safe, Effective, And Highly Acceptable Mode Of Treatment For Abnormal Uterine Bleeding Which Helps Women For A Smooth Transition To Menopause. It Is Associated With Minimal Side Effects And A High Satisfaction Rate. It Is A Very Good Alternative To Medical And Surgical Treatment For Heavy Menstrual Bleeding In Benign Conditions With High Efficacy And Cost-Effectiveness. With This Lng-Ius We Can Even Avoid The Systemic Side Effects Caused By Cocs Like Thromboembolism, Weight Gain, Mood Changes, And Breakthrough Bleeding Which Also Requires Less Skill And No Operative Morbidity. Despite All The Limitations, It Is The Best Innovative Method For The Treatment Of Abnormal Uterine Bleeding. Hence Consider Lng-Ius As A One-Stop Answer To Aub Before Deciding On A Hysterectomy.
Files
IJPCR,Vol14,Issue9,Article157.pdf
Files
(385.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:51b3366b256241a5c09b8449619a84c5
|
385.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-09-15
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue9,Article157.pdf
- Development Status
- Active
References
- 1. Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrelreleasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet 2012 ;116(1):35-8. 2. Singh K, Bharati G, Prasad D, Kumari S. Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: a conservative approach. Int J Reprod Contracept Obstet Gynecol 2017;6(2):631-5. 3. Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol 20 16;32(9):696-700. 4. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013; 368(2):128-37. 5. Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2015;(4):CD002126. 6. Garg S, Soni AA. Non-surgical lifeline for Abnormal uterine bleeding (AUB)-the LNG IUS. Indian J Obstet Gynecol Res 2016;3(1):23-7. 7. Dhamangaonkar PC, Anuradha K, Saxena A. Levonorgestrel intrauterine system (Mirena): an emerging tool for conservative treatment of abnormaluterine bleeding. Journal of Mid-Life Health 2015;6(1):26. 8. Yazbeck C, Omnes S, Vacher-Lavenu MC, Madelenat P. Levonorgestrelreleasing intrauterine system in the treatment of dysfunctional uterine bleeding: A French multicenter study. Gynecol Obstet Fertil 2006;34(10):906- 13. 9. Nayar J, Nair SS, George NA. Is LNGIUS the One-Stop Answer to AUB? J Obstet Gynaecol India 2018;68(4):253-7. 10. Mahapatra PC, Kapur A, Baxi A, Kekre A, Mediratta G, Gajaraj J. Levonorgestrel intrauterine system: a first line medical therapy for idiopathic heavy menstrual bleeding. International Journal of Reproduction, Contraception, Obstetrics and Gynecology 2015;4(5):1257-64. 11. Sushil K, Antony ZK, Mohindra V, Kapur A. Therapeutic use of LNG intrauterine system (Mirena) for menorrhagia due to benign lesions–an alternative to hysterectomy. J Obstet Gynecol India. 20 05;55:541-3. 12. Desai RM. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Midlife Health 2012;3(1):20-3. 13. Gupta B, Mittal S, Misra R, Deka D, Dadhwal V. Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleeding. Int J Gynaecol Obstet 20 06;95(3):261-6. 14. Chattopdhyay B, Nigam A, Goswami S, Chakravarty PS. Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagia. Eur Rev Med Pharmacol Sci 2011;15(7):764-8. 15. Mansukhani N, Unni J, Dua M, Darbari R, Malik S, Verma S, et al. Are women satisfied when using levonorgestrelreleasing intrauterine system for treatment of abnormal uterine bleeding? J Midlife Health 2013;4(1):31-5. 16. Atbib Y., Essad A., Zhar H., Tadlaoui Yasmina, Ait El Cadi M., & Bousliman Y. Impact de l'immunothérapie dans la prise en charge du cancer du poumon. Etude rétrospective menée à l'Hôpital Militaire d'Instruction Mohammed V- Rabat. Journal of Medical Research and Health Sciences, 2022; 5(9): 2221–2243.